<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00837915</url>
  </required_header>
  <id_info>
    <org_study_id>AA01111</org_study_id>
    <nct_id>NCT00837915</nct_id>
  </id_info>
  <brief_title>Bioequivalnce Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fasting Conditions</brief_title>
  <official_title>Comparative, Randomized, Single-Dose, Fully Replicated, 4-Way Crossover Bioavailability Study of Ranbaxy and Schering (Claritin_D® 24 Hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets, in Healthy Adult Volunteers Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ranbaxy Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ranbaxy Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to compare the single-dose relative bioavailability of&#xD;
      Ranbaxy and Schering (Claritin-D® 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg&#xD;
      Extended-Release Tablets, in a fully replicated design, under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was conducted as an open-label, randomized, Single-Dose, Fully replicated, 4-way&#xD;
      Crossover Study to compare the single-dose relative bioavailability of Ranbaxy and Schering&#xD;
      (Claritin_D® 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release&#xD;
      Tablets, in Healthy adult Volunteers Under Fasting Conditions A total of 40 subjects (30&#xD;
      males and 10 females) were included in this study, of which 36 (27 males and 9 females)&#xD;
      finished the study according to the protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">November 2002</completion_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative bioavailability between Ranbaxy and Schering (Claritin-D® 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets under fasting conditions</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets of Ranbaxy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(Claritin-D® 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult male or female volunteers, 18-45 years of age&#xD;
&#xD;
          -  Weighing at least 60 kg for males and 52 kg for females and within 15% of their ideal&#xD;
             weights (Table of &quot;Desirable Weights of Adults&quot;, Metropolitan Life Insurance Company,&#xD;
             1983);&#xD;
&#xD;
          -  Medically healthy subjects with clinically normal laboratory profiles;&#xD;
&#xD;
          -  Females of childbearing potential should either be sexually inactive (abstinent) for&#xD;
             14 days prior to the study and throughout the study or be using one of the following&#xD;
             acceptable birth control methods:&#xD;
&#xD;
               -  surgically sterile (bilateral tubal ligation, hysterectomy bilateral&#xD;
                  oophorectomy) 6 months minimum&#xD;
&#xD;
               -  IUD in place for at least 3 months&#xD;
&#xD;
               -  barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to&#xD;
                  the start of the study and .throughout the study&#xD;
&#xD;
               -  surgical sterilization of the partner (vasectomy for 6 months minimum&#xD;
&#xD;
               -  hormonal contraceptives for at least 3 months prior to the start of the study&#xD;
&#xD;
          -  Other birth control methods may be deemed acceptable.&#xD;
&#xD;
          -  Postmenopausal women with amenorrhea for at least 2 years will be eligible;&#xD;
&#xD;
          -  Voluntarily consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject candidates must not be enrolled in the study if they meet any of the following&#xD;
             criteria:&#xD;
&#xD;
          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             hematologic,gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or&#xD;
             psychiatric disease.&#xD;
&#xD;
          -  In addition, history or presence of:&#xD;
&#xD;
               -  alcoholism or drug abuse within the past year&#xD;
&#xD;
               -  hypersensitivity or idiosyncratic reaction to loratidine or any other H1-receptor&#xD;
                  antagonist&#xD;
&#xD;
               -  hypersensitivity or idiosyncratic reaction to pseudoephederine or any other&#xD;
                  sympatomimetic amines&#xD;
&#xD;
               -  glaucoma or hypermetropia&#xD;
&#xD;
          -  Subjects receiving a monoamine oxidase (MAO) inhibitor or within 14 days of stopping&#xD;
             use of an MAO inhibitor, or any sympathomimetic amines.&#xD;
&#xD;
          -  Subjects who have used any drugs or other substances known to be strong inhibitors of&#xD;
             CYP (cytochrome P450) enzymes within 10 days of study start.&#xD;
&#xD;
          -  Subjects who have used any drugs or other substances known to be strong inducers of&#xD;
             CYP (cytochrome P450) enzymes within 28 days of study start.&#xD;
&#xD;
          -  Female subjects who are pregnant or lactating.&#xD;
&#xD;
          -  Subjects who have been on an abnormal diet (for whatever reason) during the 28 days&#xD;
             prior to the first dose.&#xD;
&#xD;
          -  Subjects who, through completition of the study, would have donated in excess of:&#xD;
&#xD;
               -  500 mL of blood in 14 days, or&#xD;
&#xD;
               -  500-750 mL of blood in 14 days (unless approved by the principal Investigator),&#xD;
&#xD;
               -  1000 mL of blood in 90 days,&#xD;
&#xD;
               -  1250 mL of blood in 120 days,&#xD;
&#xD;
               -  1500 mL of blood in 180 days,&#xD;
&#xD;
               -  2000 mL of blood in 270 days,&#xD;
&#xD;
               -  2500 mL of blood in 1 days,&#xD;
&#xD;
          -  Subjects who have participated in another clinical trial within 28 days prior to the&#xD;
             study start.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MDS Pharma Services</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4R2N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.ranbaxy.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>Related Info</description>
  </link>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>February 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2009</study_first_posted>
  <last_update_submitted>February 5, 2009</last_update_submitted>
  <last_update_submitted_qc>February 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Tausif Monif</name_title>
    <organization>Ranbaxy Research Labs</organization>
  </responsible_party>
  <keyword>Bioequivaelnce Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended Release Tablets</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loratadine</mesh_term>
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

